25 Nov 2021 FIT and its 21-strong partner team go all out for more internationalization, growth and prosperity Multiple categories
23 Nov 2021 Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease Member news
22 Nov 2021 OXURION NV secures EUR 10 million convertible bond financing from Kreos Capital and Pontifax Ventures Member news
16 Nov 2021 New study demonstrates Idylla™ EGFR Mutation Test (CE-IVD) shortens time to patient management decisions for patients with non-small cell lung cancer Member news
15 Nov 2021 Biotalys’ first biocontrol Evoca™ demonstrated to be excellent new tool for growers in 2021 independent field trials Member news
15 Nov 2021 OXURION NV - First patient dosed in Part B of Phase 2 KALAHARI study evaluating multiple administrations of THR-149 versus aflibercept for treatment of Diabetic Macular Edema (DME) Member news
15 Nov 2021 Belgium has all the ingredients to be a top country for data science in health – but we have to act now! Other news
15 Nov 2021 Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis Member news
More info? Ellen Telleir Communication Coordinator linkedin.com/in/ellentelleir/ +32 9 241 80 41 ellen.telleir@flanders.bio Contact us
